0001663577-20-000429.txt : 20201123 0001663577-20-000429.hdr.sgml : 20201123 20201123164954 ACCESSION NUMBER: 0001663577-20-000429 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201123 DATE AS OF CHANGE: 20201123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SKINVISIBLE, INC. CENTRAL INDEX KEY: 0001085277 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880344219 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-25911 FILM NUMBER: 201338438 BUSINESS ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 BUSINESS PHONE: 7024337154 MAIL ADDRESS: STREET 1: 6320 S SANDHILL ROAD STREET 2: SUITE 10 CITY: LAS VEGAS STATE: NV ZIP: 89120 FORMER COMPANY: FORMER CONFORMED NAME: SKINVISIBLE INC DATE OF NAME CHANGE: 19990428 10-Q 1 skvi10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended September 30, 2020

[ ]	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from __________ to __________

	Commission File Number: 000-25911

Skinvisible, Inc.

(Exact name of Registrant as specified in its charter)

Nevada	88-0344219
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

6320 South Sandhill Road, Suite 10, Las Vegas, NV 89120

(Address of principal executive offices)

702.433.7154

(Registrant’s telephone number)

_______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

[ ] Large accelerated filer	[ ] Accelerated filer
[ ] Non-accelerated filer	[X] Smaller reporting company
	[ ] Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Securities registered pursuant to Section 12(b) of the Act: None

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 4,539,843 common shares as of November 20, 2020.

	TABLE OF CONTENTS	Page
PART I – FINANCIAL INFORMATION
Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	8
Item 4:	Controls and Procedures	8
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	9
Item 1A:	Risk Factors	9
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	\9
Item 3:	Defaults Upon Senior Securities	9
Item 4:	Mine Safety Disclosure	9
Item 5:	Other Information	9
Item 6:	Exhibits	9

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

F-1

Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019 (unaudited);

F-2

Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited);

F-3

Consolidated Statements of Stockholders’ Deficit for the nine months ended September 30, 2020 and 2019 (unaudited);

F-4

Consolidated Statements of Cash Flow for the three and nine months ended September 30, 2020 and 2019 (unaudited);

F-5

Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended September 30, 2020 are not necessarily indicative of the results that can be expected for the full year.

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2020 (Unaudited)			December 31, 2019
ASSETS
Current assets
Cash	$	11,819		$	1,298
Accounts receivable		10,848			10,204
Prepaid expense and other current assets		3,250			4,875
Total current assets		25,917			16,377

Patents and trademarks, net of accumulated amortization of $557,388 and $533,415, respectively		158,179			165,385

Total assets	$	184,096		$	181,762
					.
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities	$	842,769		$	597,291
Accounts payable related party		12,807			9,274
Accrued interest payable		890,310			491,601
Loans from related party		58,599			46,899
Loans payable		552,000			552,000
Convertible notes payable, current portion		220,000			220,000
Total current liabilities		2,576,485			1,917,065


Convertible notes payable related party, net of unamortized discount of $2,603,581 and $3,060,970 respectively		1,631,628			1,174,239

Convertible notes payable, net of current portion and unamortized debt discount of $216,289 and $254,450, respectively		135,786			97,625

Total liabilities		4,343,899			3,188,929

Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 and 4,471,746 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		4,540			4,472
Shares payable		—			59,602
Additional paid-in capital		30,241,089			30,181,555
Accumulated deficit		(34,405,432	)		(33,252,796)
Total stockholders' deficit		(4,159,803	)		(3,007,167)

Total liabilities and stockholders' deficit	$	184,096		$	181,762

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-1

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended						Nine Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019

Revenues	$	4,183		$	11,295		$	21,592		$	31,279
Revenues related party		2,633			—			121,246			1,100

Cost of revenues		—			250			—			7,199

Gross profit		6,816			11,045			142,838			25,180

Operating expenses
Amortization		4,292			10,185			23,973			29,815
Selling general and administrative		121,146			137,785			380,241			417,678
Total operating expenses		125,438			147,970			404,214			447,493

Loss from operations		(118,622	)		(136,925	)		(261,376	)		(422,313)

Other income and (expense)
Other income - related party		—			93,192			—			105,692
Loss on extinguishment of debt		—			—			—			(247,998)
Interest expense		(291,137	)		(305,009	)		(891,260	)		(710,233)
Total other expense		(291,137	)		(211,817	)		(891,260	)		(852,539)

Net loss	$	(409,759	)	$	(348,742	)	$	(1,152,636	)	$	(1,274,852)

Basic loss per common share	$	(0.09	)	$	(0.12	)	$	(0.26	)	$	(0.44)

Diluted loss per common share	$	(0.09	)	$	(0.12	)	$	(0.26	)	$	(0.44)

Basic weighted average common shares outstanding		4,471,746			2,896,689			4,476,468			2,896,689

Diluted weighted average common		4,471,746			2,896,689			4,476,468			2,896,689

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-2

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

	Common Stock
	Shares		Amount		Additional Paid-in Capital		Shares payable			Accumulated Deficit			Total Stockholders' Deficit
Balance, December 31, 2019	4,471,746	$	4,472	$	30,181,555	$	59,602		$	(33,252,796	)	$	(3,007,167)
Net loss	—		—		—		—			(430,084	)		(430,084)
Balance, March 31, 2020	4,471,746	$	4,472	$	30,181,555	$	59,602		$	(33,682,880	)	$	(3,437,251)
Net loss	—		—		—		—			(312,793	)		(312,793)
Balance, June 30, 2020	4,471,746	$	4,472	$	30,181,555	$	59,602		$	(33,995,673	)	$	(3,750,044)
Shares issued for shares payable	68,097		68		59,534		(59,602	)		—			—
Net loss	—		—		—		—			(409,759	)		(409,759)
Balance, September 30, 2020	4,539,843	$	4,540	$	30,241,089	$	—		$	(34,405,432	)	$	(4,159,803)

	Common Stock
	Shares		Amount		Additional Paid-in Capital			Shares payable		Accumulated Deficit			Total Stockholders’ Deficit
Balance, December 31, 2018	2,896,689	$	2,897	$	24,774,887		$	2,053,466	$	(31,550,665	)	$	(4,719,415)
Net loss	—		—		—			—		(343,099	)		(343,099)
Balance, March 31, 2019	2,896,689	$	2,897	$	24,774,887		$	2,053,466	$	(31,893,764	)	$	(5,062,514)
Settlement of debts	—		—		—			7,028		—			7,028
Beneficial conversion feature on convertible notes issued as settlement on existing payables	—		—		3,649,320			—		—			3,649,320
Beneficial conversion feature repurchase	—		—		(241,969	)		—		—			(241,969)
Net loss	—		—		—			—		(583,011	)		(583,011)
Balance, June 30, 2019	2,896,689	$	2,897	$	28,182,238		$	2,060,494	$	(32,476,775	)	$	(2,231,146)
Net loss	—		—		—			—		(348,742	)		(348,742)
Balance, September 30, 2019	2,896,689	$	2,897	$	28,182,238		$	2,060,494	$	(32,825,517	)	$	(2,579,888)

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-3

SKINVISIBLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended
	September 30, 2020			September 30, 2019

Cash flows from operating activities:
Net loss	$	(1,152,636	)	$	(1,274,852)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:
Amortization		23,973			29,816
Amortization of debt discount		495,550			690,886
Gain on extinguishment of debt		—			(34,972)
Changes in operating assets and liabilities:
Decrease in inventory		—			7,152
Decrease in prepaid assets		1,625			9,000
Increase in accounts receivable		(644	)		(990)
Increase in accounts payable and accrued liabilities		249,011			253,768
Increase in accrued interest		398,709			278,216
Net cash provided (used) by operating activities		15,588			(41,976)

Cash flows from investing activities:
Purchase of intangible assets		(16,767	)		(24,320)
Net cash used in investing activities		(16,767	)		(24,320)

Cash flows from financing activities:
Payments on related party loans		(15,300	)		(35,000)
Proceeds from related party loans		27,000			109,644
Net cash provided by financing activities		11,700			74,644

Net change in cash		10,521			8,348

Cash, beginning of period		1,298			2,482

Cash, end of period	$	11,819		$	10,830

Supplemental disclosure of cash flow information:
Cash paid for interest	$	—		$	17,088
Cash paid for income taxes	$	—		$	—

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Non-cash investing and financing activities:
Beneficial conversion feature on convertible debt	$	—		$	3,646,320
Common stock issued for settlement of shares payable	$	59,602		$	42,000

See Accompanying Notes to Condensed Consolidated Financial Statements.

F-4

SKINVISIBLE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development, manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations offer solutions for a broad spectrum of markets including women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

On September 26, 2017, the Company purchased 5,750,000 shares of common stock of Ovation Science Inc. (“Ovation”) for $32,286, which at the time of purchase the Company’s ownership represented 99.9% of the then issued and outstanding common stock. On March 28, 2018 the Company sold its interest in Ovation to officers of the Company for $500,000 which at the time represented a 37.80% interest in Ovation.

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

2. BASIS OF PRESENTATION AND GOING CONCERN

Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X , and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements on Form 10-K filed with the SEC on May 14, 2020. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $34,405,432 since its inception and requires capital for its contemplated operational and marketing activities to take place. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

The Company's operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States and elsewhere. The spread of COVID-19 has caused a change in

F-5

the availability of our staff and support services. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates could change in the future, as new events occur, or additional information is obtained.

3. SUMMARY OF SIGNIFICANT POLICIES

This summary of significant accounting policies of Skinvisible Inc. is presented to assist in understanding the Company’s condensed consolidated financial statements. The condensed consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the condensed consolidated financial statements.

Principles of consolidation – The condensed consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Cash and cash equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $11,189 and $1,298 in cash as of September 30, 2020 and December 31, 2019 respectively.

Fair Value of financial instruments –The carrying value of cash, accounts payable and accrued expenses, and debt (See Notes 6 & 8) approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value of $4,807,284 since the stated rate of interest approximates market rates.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.

•

Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features.

•

Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.

F-6

•

Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.

Revenue recognition – We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2020 and December 31, 2019, the Company had not recorded a reserve for doubtful accounts.

Intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

F-7

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the three and nine months ending September 30, 2020 since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 28,167,881 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2020. The shares issuable under each instrument is as follows; 100,000 shares issuable for options, 60,000 shares issuable for warrants, 28,007,881 shares issuable under convertible notes. There were 27,228,407 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2019. The shares which were issuable at that date under each instrument were as follows; 135,000 shares issuable for options, 72,000 shares issuable for warrants, 1,614,305 shares issuable for shares payable and 25,407,102 shares issuable under convertible notes.

Recently issued accounting pronouncements – The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

4. INTANGIBLE AND OTHER ASSETS

Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. As of September 30, 2020 intangible assets total $715,567, net of $557,388 of accumulated amortization. As of December 31, 2019, intangible assets total $698,800, net of $533,415 of accumulated amortization.

The Company capitalized $16,767 in patent cost during the nine months ended September 30, 2020.

Amortization expense for the three months ended September 30, 2020 and 2019 was $4,292 and $10,186, respectively.

Amortization expense for the nine months ended September 30, 2020 and 2019 was $23,973 and $29,698, respectively.

License and distributor rights were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2020.

5. STOCK OPTIONS AND WARRANTS

Stock options

The following is a summary of option activity during the nine months ended September 30, 2020.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2019		100,000		1. 51

Options granted and assumed		—		—
Options expired		—		—
Options canceled		—		—
Options exercised		—		—

Balance, September 30, 2020		100,000		1. 51

The following is a summary of option activity during the nine months ended September 30, 2019.

F-8

	Number of Shares			Weighted Average Exercise Price
Balance, December 31, 2018		161,000		$	1.80

Options granted and assumed		—			—
Options expired		(26,000	)		2.00
Options canceled		—			—
Options exercised		—			—

Balance, September 30, 2019		135,000		$	1.76

As of September 30, 2020, all stock options outstanding are exercisable.

Stock warrants

The following is a summary of warrants activity during the nine months ended September 30, 2020

	Number of Shares			Weighted Average Exercise Price
Balance, December 31, 201 9		72,200		$	1.18

Warrants granted and assumed		—			—
Warrants expired		(12,200	)		1.50
Warrants canceled		—			—
Warrants exercised		—			—

Balance, September 30, 2020		60,000		$	1.11

The following is a summary of warrants activity during the nine months ended September 30, 2019.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2018		72,200	$	1.18

Warrants granted and assumed		—		—
Warrants expired		—		—
Warrants canceled		—		—
Warrants exercised		—		—

Balance, September 30, 2019		72,200	$	1.18

As of September 30, 2020 , all stock warrants outstanding are exercisable.

F-9

6. NOTES PAYABLE

Secured debt offering

During the period from May 22, 2013 and December 31, 2018, the Company entered into a 9% notes payable to nineteen investors and received proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”

As of September 30, 2020, $552,000 of the outstanding notes payable are past due and in default and have been classified as current notes payable.

7. RELATED PARTY TRANSACTIONS

During the nine months ended September 30, 2020, $27,000 was advanced by an officer and $15,300 was repaid to another officer.

As of September 30, 2020, $58,599 in advances remained due to officers of the company. All other related party notes have been extinguished or re-negotiated as convertible notes. (See note 9 for additional details.)

License Agreement with Ovation Science for DermSafe hand sanitizer - On February 3, 2020, we entered into a License Agreement with Ovation Science Inc., a related party, pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license.

On June 10, 2020, Ovation Science Inc. paid the Company the fee otherwise due in year 3 and in exchange the Company extended the term of Ovation’s license to 6- years and granted Ovation additonal rights to its hand sanitizer products and assigned Canadian Identification Numbers 02310589 and 02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe where not currently patented. In exchange for these rights Ovation paid a $100,000 license fee. The Company completed the required assignments during the nine months ending September 30, 2020 and recognized $100,000 in revenue.

The Company earned $2,633 in royalties under the license agreement during the three months ending September 30, 2020.

The Company earned $14,114 in royalties under the license agreement during the nine months ending September 30, 2020.

The Company sold polymer products to Ovation Science Inc and earned $0 and $7,132 during the three and nine months ending September 30, 2020, respectively

F-10

8. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable consists of the following:	September 30,		December 31,
	2020		2019
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		40,000		40,000
Original issue discount		—		—
Unamortized debt discount		—		—
Total, net of unamortized discount		40,000		40,000

On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The note has reached maturity and is in default.		135,000		135,000
Unamortized debt discount		—		—
Total, net of unamortized discount		135,000		135,000

On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The note has reached maturity and is in default		20,000		20,000
Unamortized debt discount		—		—
Total, net of unamortized discount		20,000		20,000

On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default		15,000		15,000
Unamortized debt discount		—		—
Total, net of unamortized discount		15,000		15,000

F-11

On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default.	10,000		10,000
Unamortized debt discount	—		—
Total, net of unamortized discount	10,000		10,000

On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $38,161 during the nine months ended September 30, 2020 and $12,813 for the nine months ended September 30, 2019. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $12,731 during the three months ended September 30, 2020 and $12,813 for the three months ended September 30, 2019.	352,075		352,075
Unamortized debt discount	(216,289	)	(254,450)
Total, net of unamortized discount	135,786		97,625

Total Convertible Notes	$	355,786	$	317,625
Current portion:		220,000		220,000
Total long-term convertible notes	$	135,786	$	97,625

F-12

9. CONVERTIBLE NOTES PAYABLE RELATED PARTY

Convertible Notes Payable Related Party consists of the following:	September 30, 2020			December 31, 201 9
On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been amortized and charged to interest expenses as a financing expense in the amount of $457,389 during the nine months ended September 30, 2020 and 152,463 for the nine months ended September 30, 2019. The aggregate beneficial conversion feature has been amortized and charged to interest expenses as a financing expense in the amount of $152,463 during the three months ended September 30, 2020 and 152,463 for the three months ended September 30, 2019.	$	4,235,209		$	4,235,209
Unamortized debt discount		(2,603,581	)		(3,060,970	)
Total, net of unamortized discount	$	1,631,628		$	1,174,239

10. STOCKHOLDERS’ DEFICIT

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,539,843 and 4,471,746 issued and outstanding shares of common stock as of September 30, 2020 and December 31, 2019, respectively.

During the nine months ended September 30, 2020, the Company issued 68,097 shares to investors as a result of agreements settled during the year ended December 31, 2019 and recorded as stock payable valued at $59,602.

11. LICENSE AGREEMENT

On October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products.

The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire now on September 30, 2020. As of the date of this filing no payments had been received.

12. SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to September 30, 2020 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

F-13

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview

COVID-19

The full extent of the impact of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict at the present time. In an effort to contain COVID-19 or slow its spread, governments around the world have enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities. We anticipate that these actions and the global health crisis caused by COVID-19 will negatively impact business activity across the globe. While we have not observed any noticeable impact on our revenue related to these conditions in the past fiscal year, or through the date of this filing, we cannot estimate the impact COVID-19 will have in the future as business and consumer activity decelerates across the globe.

In March 2020, we enacted precautionary measures to protect the health and safety of our employees and partners. These measures include closing our office, having employees work from home, and eliminating all travel. While having employees work from home may have a negative impact on efficiency and may result in negligible increases in costs, it does have an impact on our ability to execute on our agreements to deliver our core products.

We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state, local or foreign authorities, or that we determine are in the best interests of our employees, customers, partners and stockholders. It is not clear what the potential effects any such alterations or modifications may have on our business, including the effects on our customers, partners, or vendors, or on our financial results.

Recent Developments

License with Quoin Pharmaceuticals, Inc.

The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement under the same terms to expire now on September 30, 2020. As of the date of this filing no payments had been received.

License with Ovation Science Inc.

On February 3, 2020, we entered into a License Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additonal assignment rights for its hand sanitizer products in exchange for $100,000 which was recognized as revenue during the nine months ended September 30, 2020.

Results of Operations for the Three Months Ended September 30, 2020 and 2019

Revenues

Our revenue from product sales, royalties on patent licenses and license fees (product development fees) for the three months ended September 30, 2020 was $6,186, a decrease from $11,295 for the same period ended September 30, 2019.

The decrease in revenue for three months ended September 30, 2020 was mainly due to decreased product sales. We hope to achieve increased revenues for the balance of 2020, as a result of our License Agreement with Quoin Pharmaceuticals, Inc.

Cost of Revenues

Our cost of revenues for the three months ended September 30, 2020 was $0, compared with the prior year period when cost of revenues was $250.

Our cost of revenues decreased for the three months ended September 30, 2020 over the prior year period because our revenues in 2020 were attributable to our license with Ovation Science.

Gross Profit

Gross profit for the three months ended September 30, 2020 was $6,816 , as compared with gross profit of $11,045 for the three months ended September 30, 2019.

Operating Expenses

Operating expenses decreased to $125,438 for the three months ended September 30, 2020 from $147,970 for the same period ended September 30, 2019.

Our operating expenses for the three months ended September 30, 2020 consisted mainly of accrued salaries and wages of $87,941, audit and accounting of $9,609, and amortization of $4,292. In comparison, our operating expenses for the three months ended September 30, 2019 consisted mainly of accrued salaries and wages of $87,942, audit and accounting of $9,610, rent of $15,673 and depreciation and amortization of $10,185.

Other Expenses

We had other expenses of $291,137 for the three months ended September 30, 2020, compared with other expenses of $211,817 for the three months ended September 30, 2019.

Our other expenses for the three months ended September 30, 2020 consisting entirely of $291,137 in interest expense, which includes interest expense of $125,861 and debt discount amortization of $165,276, compared with the three months ended September 30, 2019 which consisted primarily of $305,009 in interest expense which includes interest expense of $138,059 and debt discount amortization of $166,950, offset by other income from related party of $93,192.

Net Loss

We recorded a net loss of $409,759 for the three months ended September 30, 2020, as compared with a net loss of $348,742 for the three months ended September 30, 2019.

Results of Operations for the Nine Months Ended September 30, 2020 and 2019

Revenues

Our revenue from product sales, royalties on patent licenses and license fees (product development fees) for the nine months ended September 30, 2020 was $142,838, an increase from $32,379 for the same period ended September 30, 2019.

The increase in revenue for nine months ended September 30, 2020 was mainly due to our license agreement with Ovation Science. We hope to generate more revenues from this license and the license with Quoin for the rest of the year.

Cost of Revenues

Our cost of revenues for the nine months ended September 30, 2020 was $0, compared with the prior year period when cost of revenues was $7,199.

Our cost of revenues decreased for the ninemonths ended September 30, 2020 over the prior year period because our revenues in 2020 were attributable to our license with Ovation Science.

Gross Profit

Gross profit for the nine months ended September 30, 2020 was $142,838 , as compared with gross profit of $25,180 for the nine months ended September 30, 2019.

Operating Expenses

Operating expenses decreased to $404,214 for the nine months ended September 30, 2020 from $447,493 for the same period ended September 30, 2019.

Our operating expenses for the nine months ended September 30, 2020 consisted mainly of accrued salaries and wages of $263,826, audit and accounting of $55,089, and amortization of $23,973. In comparison, our operating expenses for the nine months ended September 30, 2019 consisted mainly of salaries and wages of $263,827, audit and accounting of $41,852, rent of $45,002, insurance of $11,471 and amortization and depreciation of $29,815

Other Expenses

We had other expenses of $891,260 for the nine months ended September 30, 2020, compared with other expenses of $852,539 for the nine months ended September 30, 2019.

Our other expenses for the nine months ended September 30, 2020 consisting entirely of interest expense which includes, interest expense of $395,710 and debt discount amortization of $495,550, compared with the nine months ended September 30, 2019 which consisted primarily of $710,233 in interest expense which includes, interest expense of $315,973 and debt discount amortization of $394,260 , loss on extinguishment of debts of $247,998, offset by income related party of $105,692.

Net Loss

We recorded a net loss of $1,152,636 for the nine months ended September 30, 2020, as compared with a net loss of $1,274,852 for the nine months ended September 30, 2019.

Liquidity and Capital Resources

As of September 30, 2020, we had total current assets of $25,917 and total assets in the amount of $184,096. Our total current liabilities as of September 30, 2020 were $2,576,485. We had a working capital deficit of $2,550,568 as of September 30, 2020, compared with a working capital deficit of $2,753,277 as of September 30, 2019.

Operating activities provided $15,588 in cash for the nine months ended September 30, 2020, as compared with $41,976 used for the nine months ended September 30, 2019. Our positive operating cash flow for the nine months ended September 30, 2020 is largely the result of an increase in accrued interest, accounts payable and accrued liabilities, offset mainly by our net loss for the period, compared with the nine month ended September 30, 2019, which recorded a negative operating cash flow largely as the result of our net loss for the period.

We used cash of $16,767 and $24,320 in investing activities for the nine months ended September 30, 2020 and 2019, respectively, for the purchase of intangible assets.

Cash flows provided by financing activities during the nine months ended September 30, 2020 amounted to $11,700, as compared with $74,644 for the nine months ended September 30, 2019. Our cash flows for the ninemonths ended September 30, 2020 and 2019 consisted of proceeds from related party loans.

The features of the debt instruments and payables concerning our financing activities are detailed in the footnotes to our financial statements.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred cumulative net losses of $34,405,432 since our inception and require capital for our contemplated operational and marketing activities to take place. Our ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of our contemplated plan of operations, and our transition, ultimately, to the attainment of profitable operations are necessary for us to continue operations. The ability to successfully resolve these factors raise substantial doubt about our ability to continue as a going concern. These consolidated financial statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

Off Balance Sheet Arrangements

As of September 30, 2020, there were no off balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Distribution and license rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over a five-year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2020, the Company had not recorded a reserve for doubtful accounts. The Company has $175,000 in convertible notes payable which are secured by the accounts receivable of a license agreement the Company has with Women's Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®.

Recently Issued Accounting Pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2020. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2020, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September30, 2020, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending December 31, 2020: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2020 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A.

Risk Factors

See risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2019 filed on May 14, 2020.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults upon Senior Securities

None

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None

Item 6.

Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Skinvisible, Inc.

Date:	November 23, 2020

	By: /s/ Terry Howlett Terry Howlett Title: Chief Executive Officer, Chief Financial Officer and Director

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-31.1 3 ex31_1.htm

CERTIFICATIONS

I, Terry Howlett, certify that;

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 of Skinvisible, Inc. (the “registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 23, 2020

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Executive Officer

EX-31.2 4 ex31_2.htm

CERTIFICATIONS

I, Terry Howlett, certify that;

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 of Skinvisible, Inc. (the “registrant”);

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 23, 2020

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Financial Officer

EX-32.1 5 ex32_1.htm

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Skinvisible, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission (the “Report”), I, Terry Howlett, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ Terry Howlett
Name:	Terry Howlett
Title:	Principal Executive Officer, Principal Financial Officer and Director
Date:	November 23, 2020

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EX-101.INS 6 skvi-20200930.xml XBRL INSTANCE FILE 0001085277 2020-01-01 2020-09-30 0001085277 2020-09-30 0001085277 2019-12-31 0001085277 2020-07-01 2020-09-30 0001085277 2019-07-01 2019-09-30 0001085277 2019-01-01 2019-09-30 0001085277 2018-12-31 0001085277 2019-09-30 0001085277 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001085277 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001085277 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001085277 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001085277 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001085277 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001085277 us-gaap:CommonStockMember 2018-12-31 0001085277 us-gaap:CommonStockMember 2019-03-31 0001085277 us-gaap:CommonStockMember 2019-06-30 0001085277 us-gaap:CommonStockMember 2019-09-30 0001085277 us-gaap:CommonStockMember 2019-12-31 0001085277 us-gaap:CommonStockMember 2020-03-31 0001085277 us-gaap:CommonStockMember 2020-06-30 0001085277 us-gaap:CommonStockMember 2020-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001085277 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001085277 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001085277 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001085277 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001085277 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001085277 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0001085277 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0001085277 us-gaap:TreasuryStockMember 2018-12-31 0001085277 us-gaap:TreasuryStockMember 2019-03-31 0001085277 us-gaap:TreasuryStockMember 2019-06-30 0001085277 us-gaap:TreasuryStockMember 2019-09-30 0001085277 us-gaap:TreasuryStockMember 2019-12-31 0001085277 us-gaap:TreasuryStockMember 2020-03-31 0001085277 us-gaap:TreasuryStockMember 2020-06-30 0001085277 us-gaap:TreasuryStockMember 2020-09-30 0001085277 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001085277 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001085277 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001085277 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001085277 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001085277 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001085277 us-gaap:RetainedEarningsMember 2018-12-31 0001085277 us-gaap:RetainedEarningsMember 2019-03-31 0001085277 us-gaap:RetainedEarningsMember 2019-06-30 0001085277 us-gaap:RetainedEarningsMember 2019-09-30 0001085277 us-gaap:RetainedEarningsMember 2019-12-31 0001085277 us-gaap:RetainedEarningsMember 2020-03-31 0001085277 us-gaap:RetainedEarningsMember 2020-06-30 0001085277 us-gaap:RetainedEarningsMember 2020-09-30 0001085277 2019-01-01 2019-03-31 0001085277 2019-04-01 2019-06-30 0001085277 2020-01-01 2020-03-31 0001085277 2020-04-01 2020-06-30 0001085277 2019-03-31 0001085277 2019-06-30 0001085277 2020-03-31 0001085277 2020-06-30 0001085277 2017-09-26 0001085277 SKVI:OvationScienceMember 2017-09-01 2017-09-26 0001085277 2018-03-01 2018-03-28 0001085277 1998-06-06 2020-09-30 0001085277 SKVI:OptionsMember 2020-01-01 2020-09-30 0001085277 SKVI:WarrantsMember 2020-01-01 2020-09-30 0001085277 SKVI:ConvertibleNotesMember 2020-01-01 2020-09-30 0001085277 SKVI:OptionsMember 2019-01-01 2019-09-30 0001085277 SKVI:WarrantsMember 2019-01-01 2019-09-30 0001085277 SKVI:SharesPayableMember 2019-01-01 2019-09-30 0001085277 SKVI:ConvertibleNotesMember 2019-01-01 2019-09-30 0001085277 2019-01-01 2019-12-31 0001085277 SKVI:NineteenNotesPayableMember 2013-05-22 2018-12-31 0001085277 SKVI:NineteenNotesPayableMember 2018-12-31 0001085277 SKVI:PolymerProductsMember 2020-07-01 2020-09-30 0001085277 SKVI:PolymerProductsMember 2020-01-01 2020-09-30 0001085277 SKVI:ConvertibleNote1Member 2020-09-30 0001085277 SKVI:ConvertibleNote2Member 2020-09-30 0001085277 SKVI:ConvertibleNote3Member 2020-09-30 0001085277 SKVI:ConvertibleNote4Member 2020-09-30 0001085277 SKVI:ConvertibleNote5Member 2020-09-30 0001085277 SKVI:ConvertibleNote6Member 2020-09-30 0001085277 SKVI:TotalConvertibleNotesMember 2020-09-30 0001085277 SKVI:ConvertibleNote1Member 2019-12-31 0001085277 SKVI:ConvertibleNote2Member 2019-12-31 0001085277 SKVI:ConvertibleNote3Member 2019-12-31 0001085277 SKVI:ConvertibleNote4Member 2019-12-31 0001085277 SKVI:ConvertibleNote5Member 2019-12-31 0001085277 SKVI:ConvertibleNote6Member 2019-12-31 0001085277 SKVI:TotalConvertibleNotesMember 2019-12-31 0001085277 SKVI:ConvertibleNote2Member 2020-01-01 2020-09-30 0001085277 SKVI:ConvertibleNote3Member 2020-01-01 2020-09-30 0001085277 SKVI:ConvertibleNote4Member 2020-01-01 2020-09-30 0001085277 SKVI:ConvertibleNote5Member 2020-01-01 2020-09-30 0001085277 SKVI:ConvertibleNote6Member 2020-01-01 2020-09-30 0001085277 SKVI:ConvertibleNote6Member 2019-01-01 2019-09-30 0001085277 SKVI:ConvertibleNote6Member 2020-07-01 2020-09-30 0001085277 SKVI:ConvertibleNote6Member 2019-07-01 2019-09-30 0001085277 SKVI:ConvertibleNoteOneMember 2020-09-30 0001085277 SKVI:ConvertibleNoteTwoMember 2015-10-26 0001085277 SKVI:ConvertibleNote3Member 2016-02-17 0001085277 SKVI:ConvertibleNoteFourMember 2016-08-11 0001085277 SKVI:ConvertibleNoteFiveMember 2017-01-27 0001085277 SKVI:ConvertibleNoteSixMember 2019-09-30 0001085277 SKVI:RelatedPartyNotesPayableOneMember 2020-09-30 0001085277 SKVI:RelatedPartyNotesPayableOneMember 2019-12-31 0001085277 2019-01-01 2019-06-30 0001085277 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-09-30 0001085277 us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-09-30 0001085277 us-gaap:ConvertibleNotesPayableMember 2020-07-01 2020-09-30 0001085277 us-gaap:ConvertibleNotesPayableMember 2019-07-01 2019-09-30 0001085277 2019-10-01 2019-10-17 0001085277 2020-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q false 2020-09-30 Q3 2020 --12-31 Skinvisible, Inc. 0001085277 No Non-accelerated Filer true false false 4539843

0.001

200000000

4539843

4471746

4539843

4471746

216289

254450

1631628

1174239

2603581 3060970

557388

533415

11819

1298

10830

3250

4875

25917

16377

158179

165385

184096

181762

842769

597291

12807

9274

890310

491601

58599

46899

552000

2576485

1917065

1631628

1174239

40000

135000

20000

15000

10000

352075

355786

40000

135000

20000

15000

10000

352075

317625

4235209

4343899

3188929

4540

4472

59602

30241089

30181555

-34405432

-33252796

-4159803

-3007167

184096

181762

10848

10204

135786

97625

220000

21592

4183

11295

31279

121246

2633

1100

250

7199

142838

6816

11045

25180

380241

121146

137785

417678

404214

125438

147970

447493

-261376

-118622

-136925

-422313

-93192

-105692

-247998

891260

291137

305009

710233

-1152636

-409759

-348742

-1274852

-343099

-583011

-348742

-430084

-312793

-409759

-343099

-583011

-430084

-312793

-34405432

-0.26

-0.09

-0.12

-.44

4476468

4471746

2896689

23973

4292

10185

29815

891260

291137

211817

852539

-0.26

-0.09

-0.12

-.44

4476468

4471746

2896689

495550

690886

7152

-644

-990

249011

253768

398709

278216

119278

966203

15588

-41976

16767

24320

-16767

-24320

15300

35000

27000

109644

11700

74644

10521

8348

1298 2482

17088

3646320

3649320

280076

3369244

1625

9000

-34972

59602

42000

2896689

4471746

4539843

-4159803

-3007167

-4719415

-2579888

2897

4472

4540

24774887

28182238

30181555

30241089

2053466

2060494

59602

-31550665

-31893764

-32476775

-32825517

-32252796

-33682880

-33995673

-34405432

-5062514

-2231146

-3437251

-3750044

7028

-241696

-241969

68097

59534

-59602

1.       DESCRIPTION OF BUSINESS AND HISTORY   Description of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development, manufacture and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally, the Company’s non-dermatological formulations offer solutions for a broad spectrum of markets including women’s health, pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.   History – The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.   On September 26, 2017, the Company purchased 5,750,000 shares of common stock of Ovation Science Inc. (“Ovation”) for $32,286, which at the time of purchase the Company’s ownership represented 99.9% of the then issued and outstanding common stock. On March 28, 2018 the Company sold its interest in Ovation to officers of the Company for $500,000 which at the time represented a 37.80% interest in Ovation.   Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

2.       BASIS OF PRESENTATION AND GOING CONCERN   Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X , and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements on Form 10-K filed with the SEC on May 14, 2020. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.   The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.   Going concern –   The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $34,405,432 since its inception and requires capital for its contemplated operational and marketing activities to take place. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.   The Company's operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States and elsewhere. The spread of COVID-19 has caused a change in     the availability of our staff and support services. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates could change in the future, as new events occur, or additional information is obtained.

3.       SUMMARY OF SIGNIFICANT POLICIES   This summary of significant accounting policies of Skinvisible Inc. is presented to assist in understanding the Company’s condensed consolidated financial statements. The condensed consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the condensed consolidated financial statements.     Principles of consolidation – The condensed consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.   Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.   Cash and cash equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $11,189 and $1,298 in cash as of September 30, 2020 and December 31, 2019 respectively.   Fair Value of financial instruments –The carrying value of cash, accounts payable and accrued expenses, and debt (See Notes 6 & 8) approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value of $4,807,284 since the stated rate of interest approximates market rates.   Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features. </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.</td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.</td></tr> </table>   Revenue recognition – We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).   Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2020 and December 31, 2019, the Company had not recorded a reserve for doubtful accounts.   Intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test.  Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.   Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.   Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.     Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the three and nine months ending September 30, 2020 since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 28,167,881 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2020. The shares issuable under each instrument is as follows; 100,000 shares issuable for options, 60,000 shares issuable for warrants, 28,007,881 shares issuable under convertible notes. There were 27,228,407 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2019. The shares which were issuable at that date under each instrument were as follows; 135,000 shares issuable for options, 72,000 shares issuable for warrants, 1,614,305 shares issuable for shares payable and 25,407,102 shares issuable under convertible notes.    Recently issued accounting pronouncements – The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

4.       INTANGIBLE AND OTHER ASSETS   Patents and trademarks and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful lives. As of September 30, 2020 intangible assets total $715,567, net of $557,388 of accumulated amortization. As of December 31, 2019, intangible assets total $698,800, net of $533,415 of accumulated amortization.   The Company capitalized $16,767 in patent cost during the nine months ended September 30, 2020.   Amortization expense for the three months ended September 30, 2020 and 2019 was $4,292 and $10,186, respectively.   Amortization expense for the nine months ended September 30, 2020 and 2019 was $23,973 and $29,698, respectively.   License and distributor rights were acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of September 30, 2020.

5.       STOCK OPTIONS AND WARRANTS   Stock options   The following is a summary of option activity during the nine months ended September 30, 2020.   <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2019</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1. 51</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1. 51</td></tr> </table>   The following is a summary of option activity during the nine months ended September 30, 2019.     <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2018</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">161,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.80</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(26,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.00</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.76</td></tr> </table>   As of September 30, 2020, all stock options outstanding are exercisable.   Stock warrants   The following is a summary of warrants activity during the nine months ended September 30, 2020   <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 201 9</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">72,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.18</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.50</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">60,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.11</td></tr> </table>    The following is a summary of warrants activity during the nine months ended September 30, 2019. <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">Balance, December 31, 2018</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">72,200</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.18</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">72,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.18</td></tr> </table>   As of September 30, 2020 , all stock warrants outstanding are exercisable.

6.       NOTES PAYABLE   Secured debt offering During the period from May 22, 2013 and December 31, 2018, the Company entered into a 9% notes payable to nineteen investors and received proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent rights granted for the Company's Sunscreen Products: US patent number #8,128,913: "Sunscreen Composition with Enhanced UV-A Absorber Stability and Methods.”   As of September 30, 2020, $552,000 of the outstanding notes payable are past due and in default and have been classified as current notes payable.

7.        RELATED PARTY TRANSACTIONS   During the nine months ended September 30, 2020, $27,000 was advanced by an officer and $15,300 was repaid to another officer.   As of September 30, 2020, $58,599 in advances remained due to officers of the company. All other related party notes have been extinguished or re-negotiated as convertible notes. (See note 9 for additional details.)   License Agreement with Ovation Science for DermSafe hand sanitizer - On February 3, 2020, we entered into a License Agreement with Ovation Science Inc., a related party, pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in year 3 of the agreement if it chooses to continue the license.   On June 10, 2020, Ovation Science Inc. paid the Company the fee otherwise due in Year  3 and in exchange the Company extended the term of Ovation’s license to 6 years and granted Ovation several additonal  rights to its hand sanitizer products which included  assigned Canadian Identification Numbers 02310589 and 02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe were not  currently patented. In exchange for these rights Ovation paid a $100,000 license fee. The Company completed the required assignments during the nine months ending September 30, 2020 and recognized $100,000 in revenue.   The Company earned $2,633 in royalties under the license agreement during the three months ending September 30, 2020.   The Company earned $14,114 in royalties under the license agreement during the nine months ending September 30, 2020.   The Company sold polymer products to Ovation Science Inc and earned $0 and $7,132 during the three and nine months ending September 30, 2020, respectively

8.       CONVERTIBLE NOTES PAYABLE   <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Notes Payable consists of the following:</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Original issue discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The note has reached maturity and is in default</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> </table>     <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; width: 69%">On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $38,161 during the nine months ended September 30, 2020 and $12,813 for the nine months ended September 30, 2019.   The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $12,731 during the three months ended September 30, 2020 and $12,813 for the three months ended September 30, 2019.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(216,289</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(254,450)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135,786</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">97,625</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 73%"> Total Convertible Notes</td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">355,786</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">317,625</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current portion:</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total long-term convertible notes</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">135,786</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">97,625</td></tr></table>

9.       CONVERTIBLE NOTES PAYABLE RELATED PARTY    <table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Convertible Notes Payable Related Party consists of the following:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 201 9</td></tr> <tr style="vertical-align: bottom"> <td style="width: 68%; text-align: justify; padding-bottom: 1pt">On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been amortized and charged to interest expenses as a financing expense in the amount of $457,389 during the nine months ended September 30, 2020 and 152,463 for the nine months ended September 30, 2019.   The aggregate beneficial conversion feature has been amortized and charged to interest expenses as a financing expense in the amount of $152,463 during the three months ended September 30, 2020 and 152,463 for the three months ended September 30, 2019.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">4,235,209</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">4,235,209</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,603,581</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,060,970</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,631,628</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,174,239</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr></table>

10.       STOCKHOLDERS’ DEFICIT   The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,539,843 and 4,471,746 issued and outstanding shares of common stock as of September 30, 2020 and December 31, 2019, respectively.   During the nine months ended September 30, 2020, the Company issued 68,097 shares to investors as a result of agreements settled during the year ended December 31, 2019 and recorded as stock payable valued at $59,602.

11.       LICENSE AGREEMENT   On October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory approval milestones for certain drug products.   The agreement is subject to termination, if among other things, 50% of the license fee is not paid by December 31, 2019 and if the full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31, 2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire now on September 30, 2020.  As of the date of this filing no payments had been received.

12.       SUBSEQUENT EVENTS   In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to September 30, 2020 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

Principles of consolidation – The condensed consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All significant intercompany balances and transactions have been eliminated.

Use of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Cash and cash equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $11,189 and $1,298 in cash as of September 30, 2020 and December 31, 2019 respectively.

Fair Value of financial instruments –The carrying value of cash, accounts payable and accrued expenses, and debt (See Notes 6 & 8) approximate their fair values because of the short-term nature of these instruments. Management believes the Company is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s convertible debt is also stated at a fair value of $4,807,284 since the stated rate of interest approximates market rates.   Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 1 Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets. The Company uses Level 1 measurements to value the transactions when it issues shares, warrants, options and debt with beneficial conversion features. </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 2 Quoted prices for similar assets and liabilities in active markets; quoted prices included for identical or similar assets and liabilities that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. These are typically obtained from readily available pricing sources for comparable instruments. The Company did not rely on any Level 2 measurements for any of its transactions in the periods included in these financial statements.</td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 16px"> </td> <td style="width: 13px; text-align: justify; line-height: 90%">•</td> <td style="text-align: justify">Level 3 Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on the best information available in the circumstances. The Company did not rely on any Level 3 measurements for any of its transactions in the periods included in these financial statements.</td></tr></table>

Revenue recognition – We recognize revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board's (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Product sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.   Royalty sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   Distribution and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.   The Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise taxes).

Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of September 30, 2020 and December 31, 2019, the Company had not recorded a reserve for doubtful accounts.

Intangible assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test.  Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

Income taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

Earnings (loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented for the three and nine months ending September 30, 2020 since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 28,167,881 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2020. The shares issuable under each instrument is as follows; 100,000 shares issuable for options, 60,000 shares issuable for warrants, 28,007,881 shares issuable under convertible notes. There were 27,228,407 additional shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of September 30, 2019. The shares which were issuable at that date under each instrument were as follows; 135,000 shares issuable for options, 72,000 shares issuable for warrants, 1,614,305 shares issuable for shares payable and 25,407,102 shares issuable under convertible notes.

Recently issued accounting pronouncements – The Company has evaluated all other recent accounting pronouncements and believes that none of them will have a material effect on the Company's financial position, results of operations or cash flows.

<table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; width: 69%">Balance, December 31, 2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">1. 51</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1. 51</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; width: 69%">Balance, December 31, 2018</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">161,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">1.80</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(26,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.00</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Options exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.76</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; width: 69%">Balance, December 31, 201 9</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">72,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">1.18</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1.50</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">60,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.11</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; width: 69%">Balance, December 31, 2018</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">72,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">1.18</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants granted and assumed</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants expired</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants canceled</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Balance, September 30, 2019</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">72,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.18</td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Notes Payable consists of the following:</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">September 30,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2019</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 69%; text-align: justify; padding-bottom: 1pt">$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Original issue discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">135,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The note has reached maturity and is in default</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">15,000</td></tr> </table>   <table cellpadding="0" cellspacing="0" align="center" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; width: 69%">On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">—  </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $38,161 during the nine months ended September 30, 2020 and $12,813 for the nine months ended September 30, 2019.   The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $12,731 during the three months ended September 30, 2020 and $12,813 for the three months ended September 30, 2019.</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,075</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Unamortized debt discount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(216,289</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(254,450)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total, net of unamortized discount</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135,786</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">97,625</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 73%"> Total Convertible Notes</td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">355,786</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; width: 1%">$</td> <td style="border-bottom: black 2.25pt double; width: 11%; text-align: right">317,625</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current portion:</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">220,000</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total long-term convertible notes</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">135,786</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">97,625</td></tr></table>

<table cellpadding="0" cellspacing="0" align="center" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Convertible Notes Payable Related Party consists of the following:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2020</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 201 9</td></tr> <tr style="vertical-align: bottom"> <td style="width: 68%; text-align: justify; padding-bottom: 1pt">On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.   The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been amortized and charged to interest expenses as a financing expense in the amount of $457,389 during the nine months ended September 30, 2020 and 152,463 for the nine months ended September 30, 2019.   The aggregate beneficial conversion feature has been amortized and charged to interest expenses as a financing expense in the amount of $152,463 during the three months ended September 30, 2020 and 152,463 for the three months ended September 30, 2019.</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">4,235,209</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">4,235,209</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,603,581</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,060,970</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total, net of unamortized discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,631,628</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,174,239</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1998-03-06

5750000

32286

99.9 0.3780 0.3780

500000

11189

1298

28167881

27228407

100000

60000

28007881

135000

72000

1614305

25407102

4807284

715567

698800

23973

4292

10186

29698

16676

100000

161000

135000

1.51

1.80

1.76

26000

2.00

60000

72200

1.11

1.18

12200

1.5

0.09

0.10

552000

P2Y

58599

27000

14114

2633

7132

On February 3, 2020, we entered into a License Agreement with Ovation Science Inc., a related party, pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a percentage on all net sales on the licensed products subject to adjustment in certain situations plus an extension fee of $100,000 payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, Ovation Science Inc. accelerated the extension fee and paid the Company the $100,000 otherwise due in year 3 and in exchange the Company extended the term of Ovation’s license to 6-years

100000

216289

254450

220000

40000

135000

20000

15000

10000

135786

40000

135000

20000

15000

10000

97625

2603581

3060970

2464480

40000

135000

20000

15000

10000

2017-10-26

2018-02-17

2018-08-11

2019-01-27

224064

617915

7260

64423

1473

38161

12813

12731

12813

304926

457389

152463

0.90

The promissory note is unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.

11942

110245

68097

1000000

0.50 Yes

EX-101.SCH 7 skvi-20200930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Shareholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PERESENTATION AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - INTANGIBLE AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - INTANGIBLE AND OTHER ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Options 2020 (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Options 2019 (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Warrants 2020 (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of Warrants 2019 (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY - Convertible Notes Payable Related Party Disclouser (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCKHOLDERS DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 skvi-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 skvi-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 skvi-20200930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Additional Paid-In Capital Shares Payable Accumulated Deficit Related Party Transaction [Axis] Ovation Science Inc. Options Warrants Convertible Notes Shares Payable Debt Instrument [Axis] Nineteen Notes Payable Polymer Products Convertible Note 1 Convertible Note 2 Convertible Note 3 Convertible Note 4 Convertible Note 5 Convertible Note 6 Total Convertible Notes Scenario [Axis] Convertible Note One Convertible Note Two Convertible Note Four Convertible Note Five Convertible Note Six Related Party Notes Payable Convertible Notes Payable Related Party Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash Accounts receivable Prepaid expense and other current assets Total current assets Patents and trademarks, net of accumulated amortization of $557,388 and $533,415, respectively Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities Accounts payable related party Accrued interest payable Loans from related party Loans payable Convertible notes payable, current portion Total current liabilities Convertible notes payable related party, net of unamortized discount of $2,603,581 and $3,060,970 respectively Convertible notes payable, net of current portion and unamortized debt discount of $216,289 and $254,450, respectively Total liabilities Stockholders' deficit Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 and 4,471,746 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Shares payable Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Issued Common Stock, Outstanding Convertible Notes Payable, net of unamortized debt discount Convertible Notes Payable, related party, net of unamortized discount Patents and Trademarks Accumulated Amortization Income Statement [Abstract] Revenues Revenues related party Cost of revenues Gross profit Operating expenses Amortization Selling general and administrative Total operating expenses Loss from operations Other income and (expense) Other income - related party Loss on extinguishment of debt Interest expense Total other expense Net loss Basic loss per common share Diluted loss per common share Basic weighted average common shares outstanding Diluted weighted average common Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, amount Settlement of debts Beneficial conversion feature on convertible notes issued as settlement on existing payables Beneficial conversion feature repurchase Shares issued for shares payable, shares Shares issued for shares payable, amount Ending balance, shares Ending balance, amount Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash provided (used) by operating activities: Amortization of debt discount Gain on extinguishment of debt Changes in operating assets and liabilities: Decrease in inventory Decrease in prepaid assets Increase in accounts receivable Increase in accounts payable and accrued liabilities Increase in accrued interest Net cash provided (used) by operating activities Cash flows from investing activities: Purchase of intangible assets Net cash used in investing activities Cash flows from financing activities: Payments on related party loans Proceeds from related party loans Net cash provided by financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Non-cash investing and financing activities: Beneficial conversion feature on convertible debt Common stock issued for settlement of shares payable Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND HISTORY BASIS OF PRESENTATION AND GOING CONCERN SUMMARY OF SIGNIFICANT POLICIES Notes to Financial Statements INTANGIBLE AND OTHER ASSETS Temporary Equity Disclosure [Abstract] STOCK OPTIONS AND WARRANTS NOTES PAYABLE Related Party Transactions [Abstract] EX-101.PRE 11 skvi-20200930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2020	Nov. 20, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity Registrant Name	Skinvisible, Inc.
Entity Central Index Key	0001085277
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,539,843

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash	$ 11,819	$ 1,298
Accounts receivable	10,848	10,204
Prepaid expense and other current assets	3,250	4,875
Total current assets	25,917	16,377
Patents and trademarks, net of accumulated amortization of $557,388 and $533,415, respectively	158,179	165,385
Total assets	184,096	181,762
Current liabilities
Accounts payable and accrued liabilities	842,769	597,291
Accounts payable related party	12,807	9,274
Accrued interest payable	890,310	491,601
Loans from related party	58,599	46,899
Loans payable	552,000	552,000
Convertible notes payable, current portion	220,000	220,000
Total current liabilities	2,576,485	1,917,065
Convertible notes payable related party, net of unamortized discount of $2,603,581 and $3,060,970 respectively	1,631,628	1,174,239
Convertible notes payable, net of current portion and unamortized debt discount of $216,289 and $254,450, respectively	135,786	97,625
Total liabilities	4,343,899	3,188,929
Stockholders' deficit
Common stock; $0.001 par value; 200,000,000 shares authorized; 4,539,843 and 4,471,746 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	4,540	4,472
Shares payable		59,602
Additional paid-in capital	30,241,089	30,181,555
Accumulated deficit	(34,405,432)	(33,252,796)
Total stockholders' deficit	(4,159,803)	(3,007,167)
Total liabilities and stockholders' deficit	$ 184,096	$ 181,762

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	4,539,843	4,471,746
Common Stock, Outstanding	4,539,843	4,471,746
Convertible Notes Payable, net of unamortized debt discount	$ 216,289	$ 254,450
Convertible Notes Payable, related party, net of unamortized discount	2,603,581	3,060,970
Patents and Trademarks Accumulated Amortization	$ 557,388	$ 533,415

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 4,183	$ 11,295	$ 21,592	$ 31,279
Revenues related party	2,633		121,246	1,100
Cost of revenues		250		7,199
Gross profit	6,816	11,045	142,838	25,180
Operating expenses
Amortization	4,292	10,185	23,973	29,815
Selling general and administrative	121,146	137,785	380,241	417,678
Total operating expenses	125,438	147,970	404,214	447,493
Loss from operations	(118,622)	(136,925)	(261,376)	(422,313)
Other income and (expense)
Other income - related party		93,192		105,692
Loss on extinguishment of debt				(247,998)
Interest expense	(291,137)	(305,009)	(891,260)	(710,233)
Total other expense	(291,137)	(211,817)	(891,260)	(852,539)
Net loss	$ (409,759)	$ (348,742)	$ (1,152,636)	$ (1,274,852)
Basic loss per common share	$ (0.09)	$ (0.12)	$ (0.26)	$ (.44)
Diluted loss per common share	$ (0.09)	$ (0.12)	$ (0.26)	$ (.44)
Basic weighted average common shares outstanding	4,471,746	2,896,689	4,476,468	2,896,689
Diluted weighted average common	4,471,746	2,896,689	4,476,468	2,896,689

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Shareholders Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Shares Payable	Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2018	2,896,689
Beginning balance, amount at Dec. 31, 2018	$ 2,897	$ 24,774,887	$ 2,053,466	$ (31,550,665)	$ (4,719,415)
Settlement of debts
Beneficial conversion feature on convertible notes issued as settlement on existing payables
Beneficial conversion feature repurchase
Shares issued for shares payable, shares
Shares issued for shares payable, amount
Net loss				(343,099)	(343,099)
Ending balance, shares at Mar. 31, 2019	2,896,689
Ending balance, amount at Mar. 31, 2019	$ 2,897	24,774,887	2,053,466	(31,893,764)	(5,062,514)
Beginning balance, shares at Dec. 31, 2018	2,896,689
Beginning balance, amount at Dec. 31, 2018	$ 2,897	$ 24,774,887	$ 2,053,466	$ (31,550,665)	(4,719,415)
Beneficial conversion feature on convertible notes issued as settlement on existing payables					$ 3,369,244
Ending balance, shares at Jun. 30, 2019	2,896,689
Ending balance, amount at Jun. 30, 2019	$ 2,897	$ 28,182,238	$ 2,060,494	$ (32,476,775)	$ (2,231,146)
Beginning balance, shares at Dec. 31, 2018	2,896,689
Beginning balance, amount at Dec. 31, 2018	$ 2,897	24,774,887	2,053,466	(31,550,665)	(4,719,415)
Beneficial conversion feature on convertible notes issued as settlement on existing payables					3,646,320
Net loss					(1,274,852)
Ending balance, shares at Sep. 30, 2019	2,896,689
Ending balance, amount at Sep. 30, 2019	$ 2,897	28,182,238	2,060,494	(32,825,517)	(2,579,888)
Beginning balance, shares at Mar. 31, 2019	2,896,689
Beginning balance, amount at Mar. 31, 2019	$ 2,897	24,774,887	2,053,466	(31,893,764)	(5,062,514)
Settlement of debts			7,028		7,028
Beneficial conversion feature on convertible notes issued as settlement on existing payables		3,649,320			3,649,320
Beneficial conversion feature repurchase		(241,696)			(241,969)
Shares issued for shares payable, shares
Shares issued for shares payable, amount
Net loss				$ (583,011)	$ (583,011)
Ending balance, shares at Jun. 30, 2019	2,896,689
Ending balance, amount at Jun. 30, 2019	$ 2,897	$ 28,182,238	$ 2,060,494	$ (32,476,775)	$ (2,231,146)
Settlement of debts
Beneficial conversion feature on convertible notes issued as settlement on existing payables
Beneficial conversion feature repurchase
Shares issued for shares payable, shares
Shares issued for shares payable, amount
Net loss				(348,742)	(348,742)
Ending balance, shares at Sep. 30, 2019	2,896,689
Ending balance, amount at Sep. 30, 2019	$ 2,897	28,182,238	2,060,494	(32,825,517)	(2,579,888)
Beginning balance, shares at Dec. 31, 2019	4,471,746
Beginning balance, amount at Dec. 31, 2019	$ 4,472	30,181,555	59,602	(32,252,796)	(3,007,167)
Settlement of debts
Beneficial conversion feature on convertible notes issued as settlement on existing payables
Beneficial conversion feature repurchase
Shares issued for shares payable, shares
Shares issued for shares payable, amount
Net loss				$ (430,084)	$ (430,084)
Ending balance, shares at Mar. 31, 2020	4,471,746
Ending balance, amount at Mar. 31, 2020	$ 4,472	$ 30,181,555	$ 59,602	$ (33,682,880)	$ (3,437,251)
Beginning balance, shares at Dec. 31, 2019	4,471,746
Beginning balance, amount at Dec. 31, 2019	$ 4,472	30,181,555	59,602	(32,252,796)	(3,007,167)
Beneficial conversion feature on convertible notes issued as settlement on existing payables
Net loss					(1,152,636)
Ending balance, shares at Sep. 30, 2020	4,539,843
Ending balance, amount at Sep. 30, 2020	$ 4,540	$ 30,241,089		$ (34,405,432)	$ (4,159,803)
Beginning balance, shares at Mar. 31, 2020	4,471,746
Beginning balance, amount at Mar. 31, 2020	$ 4,472	$ 30,181,555	$ 59,602	$ (33,682,880)	$ (3,437,251)
Settlement of debts
Beneficial conversion feature on convertible notes issued as settlement on existing payables
Beneficial conversion feature repurchase
Shares issued for shares payable, shares
Shares issued for shares payable, amount
Net loss				(312,793)	(312,793)
Ending balance, shares at Jun. 30, 2020	4,471,746
Ending balance, amount at Jun. 30, 2020	$ 4,472	30,181,555	59,602	(33,995,673)	(3,750,044)
Settlement of debts
Beneficial conversion feature on convertible notes issued as settlement on existing payables
Beneficial conversion feature repurchase
Shares issued for shares payable, shares	68,097
Shares issued for shares payable, amount	$ 68	59,534	(59,602)
Net loss				(409,759)	(409,759)
Ending balance, shares at Sep. 30, 2020	4,539,843
Ending balance, amount at Sep. 30, 2020	$ 4,540	$ 30,241,089		$ (34,405,432)	$ (4,159,803)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (1,152,636)	$ (1,274,852)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:
Amortization	23,973	29,815
Amortization of debt discount	495,550	690,886
Gain on extinguishment of debt		(34,972)
Changes in operating assets and liabilities:
Decrease in inventory		7,152
Decrease in prepaid assets	1,625	9,000
Increase in accounts receivable	(644)	(990)
Increase in accounts payable and accrued liabilities	249,011	253,768
Increase in accrued interest	398,709	278,216
Net cash provided (used) by operating activities	15,588	(41,976)
Cash flows from investing activities:
Purchase of intangible assets	(16,767)	(24,320)
Net cash used in investing activities	(16,767)	(24,320)
Cash flows from financing activities:
Payments on related party loans	(15,300)	(35,000)
Proceeds from related party loans	27,000	109,644
Net cash provided by financing activities	11,700	74,644
Net change in cash	10,521	8,348
Cash, beginning of period	1,298	2,482
Cash, end of period	11,819	10,830
Supplemental disclosure of cash flow information:
Cash paid for interest		17,088
Cash paid for income taxes
Non-cash investing and financing activities:
Beneficial conversion feature on convertible debt		3,646,320
Common stock issued for settlement of shares payable	$ 59,602	$ 42,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND HISTORY

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

DESCRIPTION OF BUSINESS AND HISTORY

1. DESCRIPTION OF BUSINESS AND HISTORY

Skinvisible, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

XML 19 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PERESENTATION AND GOING CONCERN

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

BASIS OF PRESENTATION AND GOING CONCERN

2. BASIS OF PRESENTATION AND GOING CONCERN

XML 20 R9.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT POLICIES

3. SUMMARY OF SIGNIFICANT POLICIES

•

XML 21 R10.htm IDEA: XBRL DOCUMENT

INTANGIBLE AND OTHER ASSETS

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

INTANGIBLE AND OTHER ASSETS

4. INTANGIBLE AND OTHER ASSETS

The Company capitalized $16,767 in patent cost during the nine months ended September 30, 2020.

Amortization expense for the three months ended September 30, 2020 and 2019 was $4,292 and $10,186, respectively.

Amortization expense for the nine months ended September 30, 2020 and 2019 was $23,973 and $29,698, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS

9 Months Ended

Sep. 30, 2020

Temporary Equity Disclosure [Abstract]

STOCK OPTIONS AND WARRANTS

5. STOCK OPTIONS AND WARRANTS

Stock options

The following is a summary of option activity during the nine months ended September 30, 2020.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2019		100,000		1. 51

Options granted and assumed		—		—
Options expired		—		—
Options canceled		—		—
Options exercised		—		—

Balance, September 30, 2020		100,000		1. 51

The following is a summary of option activity during the nine months ended September 30, 2019.

	Number of Shares			Weighted Average Exercise Price
Balance, December 31, 2018		161,000		$	1.80

Options granted and assumed		—			—
Options expired		(26,000	)		2.00
Options canceled		—			—
Options exercised		—			—

Balance, September 30, 2019		135,000		$	1.76

As of September 30, 2020, all stock options outstanding are exercisable.

Stock warrants

The following is a summary of warrants activity during the nine months ended September 30, 2020

	Number of Shares			Weighted Average Exercise Price
Balance, December 31, 201 9		72,200		$	1.18

Warrants granted and assumed		—			—
Warrants expired		(12,200	)		1.50
Warrants canceled		—			—
Warrants exercised		—			—

Balance, September 30, 2020		60,000		$	1.11

The following is a summary of warrants activity during the nine months ended September 30, 2019.

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2018		72,200	$	1.18

Warrants granted and assumed		—		—
Warrants expired		—		—
Warrants canceled		—		—
Warrants exercised		—		—

Balance, September 30, 2019		72,200	$	1.18

As of September 30, 2020 , all stock warrants outstanding are exercisable.

XML 23 R12.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

NOTES PAYABLE

6. NOTES PAYABLE

Secured debt offering

As of September 30, 2020, $552,000 of the outstanding notes payable are past due and in default and have been classified as current notes payable.

XML 24 R13.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2020

RELATED PARTY TRANSACTIONS

7. RELATED PARTY TRANSACTIONS

During the nine months ended September 30, 2020, $27,000 was advanced by an officer and $15,300 was repaid to another officer.

On June 10, 2020, Ovation Science Inc. paid the Company the fee otherwise due in Year 3 and in exchange the Company extended the term of Ovation’s license to 6 years and granted Ovation several additonal rights to its hand sanitizer products which included assigned Canadian Identification Numbers 02310589 and 02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe were not currently patented. In exchange for these rights Ovation paid a $100,000 license fee. The Company completed the required assignments during the nine months ending September 30, 2020 and recognized $100,000 in revenue.

The Company earned $2,633 in royalties under the license agreement during the three months ending September 30, 2020.

The Company earned $14,114 in royalties under the license agreement during the nine months ending September 30, 2020.

The Company sold polymer products to Ovation Science Inc and earned $0 and $7,132 during the three and nine months ending September 30, 2020, respectively

XML 25 R14.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

CONVERTIBLE NOTES PAYABLE

8. CONVERTIBLE NOTES PAYABLE

Convertible Notes Payable consists of the following:	September 30,		December 31,
	2020		2019
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		40,000		40,000
Original issue discount		—		—
Unamortized debt discount		—		—
Total, net of unamortized discount		40,000		40,000

On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The note has reached maturity and is in default.		135,000		135,000
Unamortized debt discount		—		—
Total, net of unamortized discount		135,000		135,000

On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The note has reached maturity and is in default		20,000		20,000
Unamortized debt discount		—		—
Total, net of unamortized discount		20,000		20,000

On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default		15,000		15,000
Unamortized debt discount		—		—
Total, net of unamortized discount		15,000		15,000

On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default.	10,000		10,000
Unamortized debt discount	—		—
Total, net of unamortized discount	10,000		10,000

On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $38,161 during the nine months ended September 30, 2020 and $12,813 for the nine months ended September 30, 2019. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $12,731 during the three months ended September 30, 2020 and $12,813 for the three months ended September 30, 2019.	352,075		352,075
Unamortized debt discount	(216,289	)	(254,450)
Total, net of unamortized discount	135,786		97,625

Total Convertible Notes	$	355,786	$	317,625
Current portion:		220,000		220,000
Total long-term convertible notes	$	135,786	$	97,625

XML 26 R15.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE RELATED PARTY

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

CONVERTIBLE NOTES PAYABLE RELATED PARTY

9. CONVERTIBLE NOTES PAYABLE RELATED PARTY

Convertible Notes Payable Related Party consists of the following:	September 30, 2020			December 31, 201 9
On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been amortized and charged to interest expenses as a financing expense in the amount of $457,389 during the nine months ended September 30, 2020 and 152,463 for the nine months ended September 30, 2019. The aggregate beneficial conversion feature has been amortized and charged to interest expenses as a financing expense in the amount of $152,463 during the three months ended September 30, 2020 and 152,463 for the three months ended September 30, 2019.	$	4,235,209		$	4,235,209
Unamortized debt discount		(2,603,581	)		(3,060,970	)
Total, net of unamortized discount	$	1,631,628		$	1,174,239

XML 27 R16.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

STOCKHOLDERS DEFICIT

10. STOCKHOLDERS’ DEFICIT

XML 28 R17.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

LICENSE AGREEMENT

11. LICENSE AGREEMENT

XML 29 R18.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

12. SUBSEQUENT EVENTS

XML 30 R19.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Use of Estimates

Cash and cash equivalents

Fair Value of Financial Instruments

•

Stock-based Compensation

Earnings (loss) Per Share

Recently issued accounting Pronouncments

XML 31 R20.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Tables)

9 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Temporary Equity Disclosure [Abstract]

Summary of Options

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2019		100,000		1. 51

Options granted and assumed		—		—
Options expired		—		—
Options canceled		—		—
Options exercised		—		—

Balance, September 30, 2020		100,000		1. 51

	Number of Shares			Weighted Average Exercise Price
Balance, December 31, 2018		161,000		$	1.80

Options granted and assumed		—			—
Options expired		(26,000	)		2.00
Options canceled		—			—
Options exercised		—			—

Balance, September 30, 2019		135,000		$	1.76

Summary of Warrants

	Number of Shares			Weighted Average Exercise Price
Balance, December 31, 201 9		72,200		$	1.18

Warrants granted and assumed		—			—
Warrants expired		(12,200	)		1.50
Warrants canceled		—			—
Warrants exercised		—			—

Balance, September 30, 2020		60,000		$	1.11

	Number of Shares		Weighted Average Exercise Price
Balance, December 31, 2018		72,200	$	1.18

Warrants granted and assumed		—		—
Warrants expired		—		—
Warrants canceled		—		—
Warrants exercised		—		—

Balance, September 30, 2019		72,200	$	1.18

XML 32 R21.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Tables)

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Schedule of Convertible Notes Payable

Convertible Notes Payable consists of the following:	September 30,		December 31,
	2020		2019
$40,000 face value 9% secured notes payable to investors, due in 2015. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The notes have reached maturity and are now in default, under the notes default provisions the entire balance is now due upon demand.		40,000		40,000
Original issue discount		—		—
Unamortized debt discount		—		—
Total, net of unamortized discount		40,000		40,000

On October 26, 2015 the Company issued a $135,000 face value 9% unsecured notes payable to investors, due October 26, 2017. At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of 90% of the current share price after the first anniversary of the note. The notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The note has reached maturity and is in default.		135,000		135,000
Unamortized debt discount		—		—
Total, net of unamortized discount		135,000		135,000

On February 17, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $20,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on February 17, 2018. The note is convertible at any time following 90 days after the issuance date at noteholders option into shares of our common stock at a variable conversion price of 90% of the average five day market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The holder’s ability to convert the note, however, is limited in that it will not be permitted to convert any portion of the note if the number of shares of our common stock beneficially owned by the holder and its affiliates, together with the number of shares of our common stock issuable upon any full or partial conversion, would exceed 4.99% of the Company’s outstanding shares of common stock. The note has reached maturity and is in default		20,000		20,000
Unamortized debt discount		—		—
Total, net of unamortized discount		20,000		20,000

On August 11, 2016, the Company entered into a convertible promissory note pursuant to which it borrowed $15,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on August 11, 2018. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default		15,000		15,000
Unamortized debt discount		—		—
Total, net of unamortized discount		15,000		15,000

On January 27, 2017, the Company entered into a convertible promissory note pursuant to which it borrowed $10,000. Interest under the convertible promissory note is 9% per annum, and the principal and all accrued but unpaid interest is due on January 27, 2019. The note is convertible into shares of our common stock at a variable conversion price of 90% of the average market price of our common stock during the 5 trading days prior to the notice of conversion, subject to adjustment as described in the note. The note has reached maturity and is in default.	10,000		10,000
Unamortized debt discount	—		—
Total, net of unamortized discount	10,000		10,000

On June 30, 2019, the Company renegotiated accrued salaries and interest and outstanding convertible notes for a former employee. Under the terms of the agreements, all outstanding notes totaling $224,064, accrued interest of $119,278, accrued salaries of $7,260 and accrued vacation of $1,473 were converted to a promissory note convertible into common stock with a warrant feature. The convertible promissory note is unsecured, due five years from issuance, and bears an interest rate of 10%. At the noteholder’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $280,076 as valued under the intrinsic value method. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $38,161 during the nine months ended September 30, 2020 and $12,813 for the nine months ended September 30, 2019. The aggregate beneficial conversion feature has been accreted and charged to interest expenses as a financing expense in the amount of $12,731 during the three months ended September 30, 2020 and $12,813 for the three months ended September 30, 2019.	352,075		352,075
Unamortized debt discount	(216,289	)	(254,450)
Total, net of unamortized discount	135,786		97,625

Total Convertible Notes	$	355,786	$	317,625
Current portion:		220,000		220,000
Total long-term convertible notes	$	135,786	$	97,625

XML 33 R22.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE RELATED PARTY (Tables)

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Schedule of Convertible Notes Payable Related Party

Convertible Notes Payable Related Party consists of the following:	September 30, 2020			December 31, 201 9
On June 30, 2019, the Company renegotiated accrued salaries, accrued interest, unpaid reimbursements, cash advances, and outstanding convertible notes for its two officers. Under the terms of the agreements, all outstanding notes totaling $2,464,480, accrued interest of $966,203, accrued salaries of $617,915, accrued vacation of $64,423, unpaid reimbursements of $11,942 and cash advances of $110,245 were converted to promissory notes convertible into common stock with a warrant feature. The convertible promissory notes are unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $3,369,244. The aggregate beneficial conversion feature associated with these notes has been amortized and charged to interest expenses as a financing expense in the amount of $457,389 during the nine months ended September 30, 2020 and 152,463 for the nine months ended September 30, 2019. The aggregate beneficial conversion feature has been amortized and charged to interest expenses as a financing expense in the amount of $152,463 during the three months ended September 30, 2020 and 152,463 for the three months ended September 30, 2019.	$	4,235,209		$	4,235,209
Unamortized debt discount		(2,603,581	)		(3,060,970	)
Total, net of unamortized discount	$	1,631,628		$	1,174,239

XML 34 R23.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND HISTORY (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended
	Mar. 28, 2018	Sep. 26, 2017	Sep. 30, 2020
Date of Incorporation			Mar. 06, 1998
Percent of Ovation Stock Purchased		9990.00%
Percent Ownership of interest in related party	37.80%
Sale of assets to officers	$ 500,000
Ovation Science Inc.
Common stock purchased		5,750,000
Common stock purchase price		$ 32,286
Percent Ownership of interest in related party		37.80%

XML 35 R24.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended		268 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020
Accounting Policies [Abstract]
Net loss	$ (409,759)	$ (312,793)	$ (430,084)	$ (348,742)	$ (583,011)	$ (343,099)	$ (1,152,636)	$ (1,274,852)	$ (34,405,432)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash	$ 11,189		$ 1,298
Additional shares issuable	28,167,881	27,228,407
Convertible debt, carrying amount	$ 4,807,284
Options
Shares issuable	100,000	135,000
Warrants
Shares issuable	60,000	72,000
Convertible Notes
Shares issuable	28,007,881	25,407,102
Shares Payable
Shares issuable		1,614,305

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 54
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2603-109256

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 44
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2062-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2600-109256

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2597-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 48
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 48
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 51
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e2574-109256

+ Details

XML 37 R26.htm IDEA: XBRL DOCUMENT

INTANGIBLE AND OTHER ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Notes to Financial Statements
Intangible Assets			$ 715,567		$ 698,800
Accumulated Amortization	$ 557,388		557,388		$ 533,415
Amortization Expense	4,292	$ 10,186	23,973	$ 29,698
Capitalized patent costs	$ 16,676		$ 16,676

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Summary of Options 2020 (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Stock Options And Warrants - Summary Of Options Details
Beginning Balance, number of shares	100,000	135,000	100,000	161,000
Beginning Balance, weighted average exercise price	$ 1.51	$ 1.76	$ 1.51	$ 1.80
Options granted and assumed, number of shares
Options granted and assumed, weighted average exercise price
Options expired, number of shares		26,000
Options expired, weighted average exercise price		$ 2.00
Options cancelled, number of shares
Options cancelled, weighted average exercise price
Options exercised, number of shares
Options exercised, weighted average exercise price
Ending Balance, number of shares	100,000	135,000	100,000	161,000
Ending Balance, weighted average exercise price	$ 1.51	$ 1.76	$ 1.51	$ 1.80

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Summary of Options 2019 (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Stock Options And Warrants - Summary Of Options Details
Beginning Balance, number of shares	100,000	161,000
Beginning Balance, weighted average exercise price	$ 1.51	$ 1.76	$ 1.51	$ 1.80
Options granted and assumed, number of shares
Options granted and assumed, weighted average exercise price
Options expired, number of shares		(26,000)
Options expired, weighted average exercise price		$ 2.00
Options cancelled, number of shares
Options cancelled, weighted average exercise price
Options exercised, number of shares
Options exercised, weighted average exercise price
Ending Balance, number of shares	100,000	135,000
Ending Balance, weighted average exercise price	$ 1.51	$ 1.76	$ 1.51	$ 1.80

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Summary of Warrants 2020 (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Temporary Equity Disclosure [Abstract]
Beginning balance, number of shares	60,000	72,200	72,200	72,200
Beginning balance, weighted average exercise price	$ 1.11	$ 1.18	$ 1.18	$ 1.18
Warrants granted and assumed, number of shares
Warrants granted and assumed, weighted average exercise price
Warrants expired, number of shares	12,200
Warrants expired, weighted average exercise price	$ 1.5
Warrants cancelled, number of shares
Warrants cancelled, weighted average exercise price
Warrants exercised, number of shares
Warrants exercised, weighted average exercise price
Ending balance, number of shares	60,000	72,200	72,200	72,200
Ending balance, weighted average exercise price	$ 1.11	$ 1.18	$ 1.18	$ 1.18

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Summary of Warrants 2019 (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Temporary Equity Disclosure [Abstract]
Beginning balance, number of shares	60,000	72,200	72,200	72,200
Beginning balance, weighted average exercise price	$ 1.11	$ 1.18	$ 1.18	$ 1.18
Warrants granted and assumed, number of shares
Warrants granted and assumed, weighted average exercise price
Warrants expired, number of shares	12,200
Warrants expired, weighted average exercise price	$ 1.5
Warrants cancelled, number of shares
Warrants cancelled, weighted average exercise price
Warrants exercised, number of shares
Warrants exercised, weighted average exercise price
Ending balance, number of shares	60,000	72,200	72,200	72,200
Ending balance, weighted average exercise price	$ 1.11	$ 1.18	$ 1.18	$ 1.18

XML 42 R31.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)	67 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2020	Dec. 31, 2019
Current notes payable		$ 552,000	$ 552,000
Nineteen Notes Payable
Notes payable, interest rate	9.00%
Notes payable, proceeds	$ 552,000
Notes payable, term	2 years

XML 43 R32.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Due to Officers	$ 58,599	$ 58,599
Officer Advanced		27,000
Royalties earned	2,633	14,114
Repayment to officer		$ (15,300)	$ (35,000)
License agreement description		On February 3, 2020, we entered into a License Agreement with Ovation Science Inc., a related party, pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a percentage on all net sales on the licensed products subject to adjustment in certain situations plus an extension fee of $100,000 payable in year 3 of the agreement if it chooses to continue the license. On June 10, 2020, Ovation Science Inc. accelerated the extension fee and paid the Company the $100,000 otherwise due in year 3 and in exchange the Company extended the term of Ovation’s license to 6-years
Revenue from distribution agreement	100,000
Polymer Products
Royalties earned	$ 0	$ 7,132

XML 44 R33.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE - Schedule of Conversions of Stock (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Convertible note payable	$ 1,631,628	$ 1,174,239
Convertible Note 3
Convertible note payable		20,000
Unamortized debt discount
Total Net of Unamortized Discount		20,000
Convertible Note 1
Convertible note payable	40,000	40,000
Original issue discount
Unamortized debt discount
Total Net of Unamortized Discount	40,000	40,000
Convertible Note 2
Convertible note payable	135,000	135,000
Unamortized debt discount
Total Net of Unamortized Discount	135,000	135,000
Convertible Note 3
Convertible note payable	20,000
Unamortized debt discount
Total Net of Unamortized Discount	20,000
Convertible Note 4
Convertible note payable	15,000	15,000
Unamortized debt discount
Total Net of Unamortized Discount	15,000	15,000
Convertible Note 5
Convertible note payable	10,000	10,000
Unamortized debt discount
Total Net of Unamortized Discount	10,000	10,000
Convertible Note 6
Convertible note payable	352,075	352,075
Unamortized debt discount	(216,289)	(254,450)
Total Net of Unamortized Discount	135,786	97,625
Total Convertible Notes
Convertible note payable	355,786	317,625
Convertible notes payable current	220,000	220,000
Total Net of Unamortized Discount	$ 135,786	$ 97,625

XML 45 R34.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jan. 27, 2017	Aug. 11, 2016	Feb. 17, 2016	Oct. 26, 2015
Convertible Notes Payable, Value					$ 2,464,480		$ 2,464,480
Accrued salaries					617,915		617,915
Accrued vacation					64,423		64,423
Accrued Interest							966,203	$ 398,709	$ 278,216
Beneficial conversion feature on convertible debt					$ 3,649,320		3,369,244		3,646,320
Financing expense							$ 304,926
Convertible Note 2
Due date for unpaid interest								Oct. 26, 2017
Convertible Note 3
Convertible Notes Payable, Value												$ 20,000
Interest Rate												9.00%
Due date for unpaid interest								Feb. 17, 2018
Discount Of Current Share Price												90.00%
Convertible Note 4
Due date for unpaid interest								Aug. 11, 2018
Convertible Note 5
Due date for unpaid interest								Jan. 27, 2019
Convertible Note 6
Accrued Interest								$ 119,278
Beneficial conversion feature on convertible debt								280,076
Financing expense	12,731			$ 12,813				38,161	$ 12,813
Convertible Note One
Convertible Notes Payable, Value	$ 40,000							$ 40,000
Interest Rate	9.00%							9.00%
Discount Of Current Share Price	90.00%							90.00%
Convertible Note Two
Convertible Notes Payable, Value													$ 135,000
Interest Rate													9.00%
Discount Of Current Share Price													90.00%
Convertible Note Four
Convertible Notes Payable, Value											$ 15,000
Interest Rate											9.00%
Discount Of Current Share Price											90.00%
Convertible Note Five
Convertible Notes Payable, Value										$ 10,000
Interest Rate										9.00%
Discount Of Current Share Price										90.00%
Convertible Note Six
Interest Rate				10.00%					10.00%
Outstanding notes value				$ 224,064					$ 224,064
Accrued salaries				7,260					7,260
Accrued vacation				$ 1,473					$ 1,473

XML 46 R35.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE RELATED PARTY - Convertible Notes Payable Related Party Disclouser (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Convertible notes payable	$ 1,631,628	$ 1,174,239
Total, net of Unamortized Discount	216,289	254,450
Related Party Notes Payable
Convertible notes payable	4,235,209	4,235,209
Unamortized debt discount	(2,603,581)	(3,060,970)
Total, net of Unamortized Discount	$ 1,631,628	$ 1,174,239

XML 47 R36.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE RELATED PARTY (Details Narrative) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Convertible Notes Payable, Value					$ 2,464,480		$ 2,464,480
Conversion terms							The promissory note is unsecured, due five years from issuance, and bear an interest rate of 10%. At the investor’s option until the repayment date, the note may be converted to shares of the Company’s common stock at a fixed price of $0.20 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.30 per share for three years after the conversion date.
Accrued salaries					617,915		$ 617,915
Accrued vacation					64,423		64,423
Accrued Interest							966,203	$ 398,709	$ 278,216
Unpaid reimbursements					11,942		11,942
Cash advances					110,245		110,245
Beneficial conversion feature on convertible debt					$ 3,649,320		3,369,244		3,646,320
Financing Expense							$ 304,926
Convertible Notes Payable Related Party
Financing Expense	$ 152,463			$ 152,463				$ 457,389	$ 152,463

XML 48 R37.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	4,539,843	4,471,746
Shares remaining to be issued	68,097	68,097
Stock payable		$ 59,602

XML 49 R38.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENT (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
LICENSE AGREEMENT (Details Narrative) - USD ($)	Oct. 17, 2019	Sep. 30, 2020
Business Combinations [Abstract]
License fee	$ 1,000,000
Percent payment due to avoid termination of license agreement		50.00%

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

3^Y^&UH-D.#VROTU_%L/KG[#0BMO30@@\245"1=@14&SX+[ M*"!S$R_*]F#X045:)7L/QC=X?T!Y<)K X49P,]W!;#RC[6!Z-YK1I3IK%[0M M?)R,;S^BX>1V.+J[A=$B#N(^1);OS^<7QMR#.#K[],LO@[O?*$MGXX^WX^OQ M<' [1]/)S7@X'LV.M%=_2Z^JF,>%U\ +J_2FLLFKL9:U77QS$ZHM?;V*8R7![^W'\X6;$!MS)_*^C.S28S4;S@_NT?H@XQ^M-G'C);S$S1,O2ND^81SI'-YZ-;O'Q,R,:!X54^N H9@A MT#;7"C7$]%!=$=Q@*;/0O%OK5 ($9AIV?QW4P?/5O)N\&]T,YJ,KTE'>S7]# M44! ,D53HC F$&IT8##KEJQ[-S*XM9/6& R' MQET�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